Company Focus

Daiichi Sankyo

Latest Daiichi Sankyo News

AstraZeneca withdraws EU submission for lung cancer drug
Biotechnology
AstraZeneca and development partner Daiichi Sankyo have withdrawn a marketing authorization application for datopotamab deruxtecan (Dato-DXd) in lung cancer.   24 December 2024


Latest News & Features of interest to Daiichi Sankyo

Latest In Brief for Daiichi Sankyo

Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD).   5 December 2024

Latest Relevant Ones To Watch News

Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners.   17 December 2024

More in M&A >


Relevant Ones to Watch Companies

Reset all filters
Refine Search